Modulation of transforming growth factor beta expression and induction of apoptosis by tamoxifen in ER positive and ER negative breast cancer cells

Tamoxifen and TGF-beta in Breast Cancer

publication

Author Information

Author(s): JR Benson, M Baum

Primary Institution: The Royal Marsden Hospital

Hypothesis

Tamoxifen modulates TGF-beta expression in both ER-positive and ER-negative breast cancer cells through mechanisms that may be independent of the estrogen receptor.

Conclusion

The study suggests that tamoxifen can induce TGF-beta expression in breast cancer cells, potentially through both transcriptional and post-transcriptional mechanisms.

Supporting Evidence

  • Tamoxifen induced TGF-beta in both ER-positive and ER-negative breast cancer cells.
  • Previous studies showed that TGF-beta induction by tamoxifen was primarily observed in MCF-7 cells.
  • High concentrations of tamoxifen may lead to cytotoxic effects rather than just activating pathways for TGF-beta production.

Takeaway

Tamoxifen, a breast cancer treatment, can help increase a protein called TGF-beta in cancer cells, which might help slow down their growth.

Methodology

The study involved in vitro experiments examining the effects of tamoxifen on TGF-beta expression in breast cancer cells.

Limitations

The concentrations of tamoxifen used were relatively high, which may lead to non-specific cytotoxic effects.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication